Muchos de los artículos tienen comentarios en el blog de nuestro compañero el Dr. Mateu Seguí, y aportaciones de otros miembros del grupo o expertos en DM. Síguelos
Diciembre 2013
Standards of Medical Care in Diabetes 2014. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014.
Las sulfonilureas en monoterapia según la Cochrane Database
Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013 Apr 30;4:CD009008. doi: 10.1002/14651858.CD009008.pub2.
Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013 Oct;30(10):1160-71. doi: 10.1111/dme.12232.
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013 Apr 17. doi: 10.1111/dom.12116. [Epub ahead of print]
Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013 Apr 30;4:CD009008. doi: 10.1002/14651858.CD009008.pub2.
Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013 Oct;30(10):1160-71. doi: 10.1111/dme.12232.
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013 Apr 17. doi: 10.1111/dom.12116. [Epub ahead of print]
Diferencias entre las ecuaciones de riesgo cardiovascular derivadas del SCORE para nuestro país.
Brotons C, Moral I, Soriano N, Cuixart L, Osorio D, Bottaro D, Puig M, Joaniquet X, Marcos A, Casasa A. Impact of Using Different SCORE Tables for Estimating Cardiovascular Risk. Rev Esp Cardiol. 2013 Nov 19. pii: S0300-8932(13)00365-5. doi: 10.1016/j.recesp.2013.06.021. [Epub ahead of print].
Goff DC Jr, Lloyd-Jones DM, Bennett G, O'Donnell CJ, Coady S, Robinson J, D'Agostino RB Sr, Schwartz JS, Gibbons R, Shero ST, Greenland P, Smith SC Jr, Lackland DT, Sorlie P, Levy D, Stone NJ, Wilson PW. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Nov 7. pii: S0735-1097(13)06031-2. doi: 10.1016/j.jacc.2013.11.005. [Epub ahead of print]
Brotons C, Moral I, Soriano N, Cuixart L, Osorio D, Bottaro D, Puig M, Joaniquet X, Marcos A, Casasa A. Impact of Using Different SCORE Tables for Estimating Cardiovascular Risk. Rev Esp Cardiol. 2013 Nov 19. pii: S0300-8932(13)00365-5. doi: 10.1016/j.recesp.2013.06.021. [Epub ahead of print].
Goff DC Jr, Lloyd-Jones DM, Bennett G, O'Donnell CJ, Coady S, Robinson J, D'Agostino RB Sr, Schwartz JS, Gibbons R, Shero ST, Greenland P, Smith SC Jr, Lackland DT, Sorlie P, Levy D, Stone NJ, Wilson PW. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Nov 7. pii: S0735-1097(13)06031-2. doi: 10.1016/j.jacc.2013.11.005. [Epub ahead of print]
Documento sobre el manejo de las hipoglucemias de la Sociedad Española de Endocrinología y Nutrición (SEEN). Mezquita-Raya P, Reyes-García R, Moreno-Pérez O, Muñoz-Torres M, Merino-Torres JF, Gorgojo-Martínez JJ,et al; Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición (SEEN). Position statement: Hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition. Endocrinol Nutr. 2013 Nov;60(9):517.e1-517.e18. doi: 10.1016/j.endonu.2013.04.005. Epub 2013 Aug 1.
Calibración del UKPDS Risk Engine en el riesgo coronario. Bannister CA, Poole CD, Jenkins-Jones S, Morgan CL, Elwyn G, Spasic I, Currie CJ. External Validation of the UKPDS Risk Engine in Incident Type 2 Diabetes: a need for new risk type 2 diabetes-specific risk equations. Diabetes Care. 2013 Oct 2. [Epub ahead of print]
Las sulfonilureas y el riesgo cardiovascular. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013 Oct;30(10):1160-71. doi: 10.1111/dme.12232.
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013 Apr 17. doi: 10.1111/dom.12116. [Epub ahead of print]
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013 Apr 17. doi: 10.1111/dom.12116. [Epub ahead of print]
La metformina mejora la supervivencia de pacientes diabéticos con cáncer. Yin M, Zhou J, Gorak EJ, Quddus F. Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis.Oncologist. 2013 Nov 20. [Epub ahead of print]
Noviembre 2013
Disminuyen las restricciones para la prescripción de la rosiglitazona en USA. FDA lifts some safety restrictions on GlaxoSmithKline's Avandia
La Guía de Práctica Clínica del ACC/AHA para el cálculo del riesgo cardiovascular. Goff DC Jr, Lloyd-Jones DM, Bennett G, O'Donnell CJ, Coady S, Robinson J, D'Agostino RB Sr, Schwartz JS, Gibbons R, Shero ST, Greenland P, Smith SC Jr, Lackland DT, Sorlie P, Levy D, Stone NJ, Wilson PW. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Nov 7. pii: S0735-1097(13)06031-2. doi: 10.1016/j.jacc.2013.11.005. [Epub ahead of print]
Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW.2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Nov 12. [Epub ahead of print]
Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW.2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Nov 12. [Epub ahead of print]
Nuevas recomendaciones para el tratamiento del colesterol de la American College of Cardiology/American Heart Association. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013
La dieta mediterránea con baja carga glucémica disminuye el riesgo de diabetes tipo 2. Rossi M, Turati F, Lagiou P, Trichopoulos D, Augustin LS, La Vecchia C, Trichopoulou A. Mediterranean diet and glycaemic load in relation to incidence of type 2 diabetes: results from the Greek cohort of the population-based European Prospective Investigation into Cancer and Nutrition (EPIC). Diabetologia. 2013 Nov;56(11):2405-13. doi: 10.1007/s00125-013-3013-y. Epub 2013 Aug 22.
Umbrales tensionales de la Cochrane Collaboration para el individuo con diabetes tipo 2. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev. 2013 Oct 30;10:CD008277. Doi: 10.1002/14651858.CD008277.pub2.
¿El ayuno intermitente puede ser útil en el control del peso corporal? James E Brown, Michael Mosley, Sarah Aldred. Intermittent Fasting A Dietary Intervention for Prevention of Diabetes and Cardiovascular Disease?. British Journal of Diabetes and Vascular Disease. 2013;13(2):68-72.
Los inhibidores de la enzima convertidora de la angiotensina serían los mejores antihipertensivos en el tratamiento del paciente con diabetes tipo 2. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013 Oct 24;347:f6008. doi: 10.1136/bmj.f6008.
La intervención sobre los estilos de vida en los individuos con riesgo de diabetes tipo 2. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle Interventions for Patients With and at Risk for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2013 Oct 15;159(8):543-51. doi: 10.7326/0003-4819-159-8-201310150-00007.
Octubre 2013
Los conflictos de intereses de los autores y las recomendaciones de las Guías de Práctica Clínica. Norris SL, Holmer HK, Ogden LA, Burda BU, Fu R. Conflicts of Interest among Authors of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus. PLoS One. 2013 Oct 14;8(10):e75284. doi: 10.1371/journal.pone.0075284.
Cuidado con utilizar los reservorios de insulina (plumas, pen, cartuchos) por más de una persona. Schaefer MK, Kossover RA, Perz JF. Sharing insulin pens: are you putting patients at risk? Diabetes Care. 2013 Nov;36(11):e188-9. doi: 10.2337/dc13-1522.. CDC Clinical Reminder: Insulin Pens Must Never Be Used for More than One Person
Se necesitan más factores de riesgo que la presión arterial para el cribado de la diabetes tipo 2. Norris SL, Kansagara D, Bougatsos C, Fu R; U.S. Preventive Services Task Force. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Jun 3;148(11):855-68.
Casagrande SS, Cowie CC, Fradkin JE. Utility of the U.S. Preventive Services Task Force criteria for diabetes screening. Am J Prev Med. 2013 Aug;45(2):167-74. doi: 10.1016/j.amepre.2013.02.026.
Casagrande SS, Cowie CC, Fradkin JE. Utility of the U.S. Preventive Services Task Force criteria for diabetes screening. Am J Prev Med. 2013 Aug;45(2):167-74. doi: 10.1016/j.amepre.2013.02.026.
Recomendaciones sobre la dieta en la diabetes según la evidencia científica. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, Neumiller JJ, Nwankwo R, Verdi CL, Urbanski P, Yancy WS Jr. Nutrition Therapy Recommendations for the Management of Adults With Diabetes. Diabetes Care. 2013 Oct 9. [Epub ahead of print]
La dieta mediterránea es capaz de disminuir el riesgo de accidente vásculocerebral en personas genéticamente predispuestas.Corella D, Carrasco P, Sorlí JV, Estruch R, Rico-Sanz J, Martínez-González MA, Salas-Salvadó J, Covas MI, Coltell O, Arós F, Lapetra J, Serra-Majem L, Ruiz-Gutiérrez V, Warnberg J, Fiol M, Pintó X, Ortega-Azorín C, Muñoz MA, Martínez JA, Gómez-Gracia E, González JI, Ros E, Ordovás JM.Mediterranean Diet Reduces the Adverse Effect of the TCF7L2-rs7903146 Polymorphism on Cardiovascular Risk Factors and Stroke Incidence: A randomized controlled trial in a high-cardiovascular-risk population. Diabetes Care. 2013 Sep 16. [Epub ahead of print]
La inercia clínica se da en un 33,2% de los pacientes con diabetes tipo 2. Mata-Cases M, Benito-Badorrey B, Roura-Olmeda P, Franch-Nadal J, Pepió-Vilaubí JM, Saez M, Coll-de-Tuero G; on behalf of the GEDAPS (Primary Care Group for the study of Diabetes) of the Catalonian Society of Family and Community Medicine. Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care. Curr Med Res Opin. 2013 Sep 6. [Epub ahead of print]
El consumo de carne roja aumenta el riesgo de debutar con diabetes tipo 2. Pan A, Sun Q, Bernstein AM, Manson JE, Willett WC, Hu FB. Changes in red meat consumption and subsequent risk of type 2 diabetes mellitus: three cohorts of US men and women.JAMA Intern Med. 2013 Jul 22;173(14):1328-35. doi: 10.1001/jamainternmed.2013.6633.
Supone la metfomina en el paciente añoso un factor de riesgo de demencia. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, et al; AIBL Investigators. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care. 2013 Oct;36(10):2981-7. doi: 10.2337/dc13-0229. Epub 2013 Sep 5.
Septiembre 2013
¿Es la HbA1c un marcador de enfermedad renal y cardiovascular en la población general? Hernandez D, Espejo-Gil A, Bernal-Lopez MR, Mancera-Romero J, Baca-Osorio AJ, Tinahones FJ, Armas-Padron AM, Ruiz-Esteban P, Torres A, Gomez-Huelgas R. Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC Nephrol. 2013 Jul 17;14(1):151. [Epub ahead of print]
¿Es útil el consumo de canela para el control metabólico de la Diabetes tipo 2? Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ .Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Ann Fam Med. 2013 Sep-Oct;11(5):452-9. doi: 10.1370/afm.1517.
La inercia clínica en intensificación del tratamiento del diabético tipo 2. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care. 2013 Jul 22. [Epub ahead of print]
Los inhibidores de la dipeptidil peptidasa-4 (DPP-4) y el riesgo cardiovascular. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mozenson O, McGuire DK, Ray KK, Leiter LA, Raz I; the SAVOR-TIMI 53 Steering Committee and Investigators.Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013 Sep 2. [Epub ahead of print]
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; the EXAMINE Investigators. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013 Sep 2. [Epub ahead of print]
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; the EXAMINE Investigators. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013 Sep 2. [Epub ahead of print]
Actualización de la U.S. Preventive Services Task Force en cuanto al cribado de la enfermedad arterial periférica mediante el índice tobillo-brazo.
- Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2013 Sep 3;159(5):I-28. doi: 10.7326/0003-4819-159-5-201309030-00002.
-Lin JS, Olson CM, Johnson ES, Whitlock EP. The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S Preventive services task force. Ann Intern Med. 2013 Sep 3;159(5):333-41. doi: 10.7326/0003-4819-159-5-201309030-00007.
- Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2013 Sep 3;159(5):I-28. doi: 10.7326/0003-4819-159-5-201309030-00002.
-Lin JS, Olson CM, Johnson ES, Whitlock EP. The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S Preventive services task force. Ann Intern Med. 2013 Sep 3;159(5):333-41. doi: 10.7326/0003-4819-159-5-201309030-00007.
Consumo de fruta y riesgo de diabetes tipo 2. Muraki I, Imamura F, Manson JE, Hu FB, Willett WC, van Dam RM, Sun Q. Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. BMJ. 2013 Aug 28;347:f5001. doi: 10.1136/bmj.f5001.
La pérdida de peso reduce la incidencia de diabetes y la mortalidad
Franco M, Bilal U, Orduñez P, Benet M, Morejón A, Caballero B, Kennelly JF, Cooper RS. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980-2010: repeated cross sectional surveys and ecological comparison of secular trends. BMJ. 2013 Apr 9;346:f1515. doi: 10.1136/bmj.f1515.
Franco M, Bilal U, Orduñez P, Benet M, Morejón A, Caballero B, Kennelly JF, Cooper RS. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980-2010: repeated cross sectional surveys and ecological comparison of secular trends. BMJ. 2013 Apr 9;346:f1515. doi: 10.1136/bmj.f1515.
¿Influye la temperatura del cocinado en la insulinorresistencia?Mark AB, Poulsen MW, Andersen S, Andersen JM, Bak MJ, Ritz C, Holst JJ, Nielsen J, de Courten B, Dragsted LO, Bügel S.Consumption of a Diet Low in Advanced Glycation Endproducts for 4 weeks Improves Insulin Sensitivity in Overweight Women. Diabetes Care. 2013 Aug 19. [Epub ahead of print]
Mayor mortalidad con las sulfonilureas o la rosiglitazona en comparación con la metformina. Wheeler S, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, Boyko EJ. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia. 2013 Jun 25. [Epub ahead of print]
Agosto 2013
Los inhibidores de los co-transportadores de la bomba de sodio-glucosa a nivel renal- Una nueva familia en el arsenal terapéutico. Vasilakou D, et al Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis. Ann Intern Med. 2013;159(4):262-274. doi:10.7326/0003-4819-159-4-201308200-00007
¿Cuál es el intervalo de cribado para prevenir y tratar precozmente las retinopatías diabéticas que amenazan la visión?Echouffo-Tcheugui JB, Ali MK, Roglic G, Hayward RA, Venkat Narayan KM.Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. Diabet Med. 2013 Jul 2. doi: 10.1111/dme.12274. [Epub ahead of print]
Nueva actualización de la Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.
La EMA anuncia que no existen nuevas evidencias que relacionen los derivados incretínicos con patología pancreática. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with increased Exocrine Pancreas Dysplasia and the potential for Glucagon-producing Neuroendocrine Tumors.Diabetes. 2013 Mar 22. [Epub ahead of print]
EMA announcement.
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB.Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013 Apr 8;173(7):534-9. doi: 10.1001/jamainternmed.2013.2720.
EMA announcement.
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB.Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013 Apr 8;173(7):534-9. doi: 10.1001/jamainternmed.2013.2720.
Julio 2013
¿Cuánto dura la remisión de la diabetes tipo 2 tras la cirugía bariátrica? Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, O'Connor PJ, Theis MK, Campos GM, McCulloch D, Selby J.A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013 Jan;23(1):93-102. doi: 10.1007/s11695-012-0802-1.
La ingesta de carbohidratos refinados influye en el comportamiento alimentario. Lennerz BS, Alsop DC, Holsen LM, Stern E, Rojas R, Ebbeling CB, Goldstein JM, Ludwig DS.Effects of dietary glycemic index on brain regions related to reward and craving in men.Am J Clin Nutr. 2013 Jun 26. [Epub ahead of print]
Declaración sobre los determinantes socioecológicos en el riesgo de diabetes tipo 2 y la prediabetes. Hill JO, Galloway JM, Goley A, Marrero DG, Minners R, Montgomery B, Peterson GE, Ratner RE, Sanchez E, Aroda VR. Scientific Statement: Socioecological Determinants of Prediabetes and Type 2 Diabetes. Diabetes Care. 2013 Jun 20. [Epub ahead of print]
Junio 2013
Se han publicado los resultados del estudio Look AHEAD que fue detenido prematuramenteThe Look AHEAD Research Group. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. N Engl J Med. 2013 Jun 24. [Epub ahead of print]
¿Se precisa una revisión independiente de los riesgos de los derivados incretínicos? ADA: Independent Review of Incretins and Pancreatitis, Cancer
La saxagliptina no es inferior al placebo en la producción de eventos cardiovasculares en pacientes de alto riesgo cardiovascular. AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza® (saxagliptin)
Diferencias en los resultados entre los análogos GLP-1 y la insulina basal en Atención Primaria. Hall GC, McMahon AD, Dain MP, Wang E, Home PD. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med. 2013 Jun;30(6):681-6. doi: 10.1111/dme.12137.
La marihuana disminuye la insulinorresistencia. Penner EA, Buettner H, Mittleman MA. The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults. Am J Med. 2013 May 9. pii: S0002-9343(13)00200-3. doi: 10.1016/j.amjmed.2013.03.002. [Epub ahead of print].
El riesgo de tener diabetes tipo 2 depende del tipo de estatina. Danaei G, García Rodríguez LA, Fernandez Cantero O, Hernán MA. Statins and Risk of Diabetes: An analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care. 2013 May;36(5):1236-40. doi: 10.2337/dc12-1756. Epub 2012 Dec 17.
¿Podría volverse a autorizar la rosiglitazona? http://redgedaps.blogspot.com.es/2013/06/podria-volverse-autorizar-la.html
¿Influye la insulina en la arteriosclerosis? Monnier L, Hanefeld M, Schnell O, Colette C, Owens D. Insulin and atherosclerosis: how are they related?. Diabetes Metab. 2013 Apr;39(2):111-7. doi: 10.1016/j.diabet.2013.02.001. Epub 2013 Mar 15.
Mayo 2013
Las sulfonilureas y la seguridad cardiovascular Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013 Apr 17. doi: 10.1111/dom.12116. [Epub ahead of print]
La betatrofina, una esperanza en la regeneración de las células β pancreáticas. Yi P, Park JS, Melton DA.Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation. Cell. 2013 Apr 24. pii: S0092-8674(13)00449-2. doi: 10.1016/j.cell.2013.04.008. [Epub ahead of print]
¿Existe asociación entre el consumo de orlistat y lesión hepática? Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013 Apr 12;346:f1936. doi: 10.1136/bmj.f1936.
¿Son las estatinas o los niveles de LDL-colesterol los que previenen los ataques cardíacos? Ledford H. Cholesterol limits lose their lustre.
Nature. 2013 Feb 28;494(7438):410-1. doi: 10.1038/494410a.
Nature. 2013 Feb 28;494(7438):410-1. doi: 10.1038/494410a.
Abril 2013
¿Aumenta la cirugía bariátrica el riesgo de cáncer colorrectal?
Derogar M, Hull MA, Kant P, Ostlund M, Lu Y, Lagergren J. Increased Risk of Colorectal Cancer After Obesity Surgery.
Derogar M, Hull MA, Kant P, Ostlund M, Lu Y, Lagergren J. Increased Risk of Colorectal Cancer After Obesity Surgery.
¿Son adecuados los criterios para diagnosticar la diabetes gestacional? Langer O, Umans JG, Miodovnik M. Perspectives on the proposed gestational diabetes mellitus diagnostic criteria. Obstet Gynecol. 2013 Jan;121(1):177-82. doi: http://10.1097/AOG.0b013e31827711e5.
HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA, Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991–2002
International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy
HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA, Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991–2002
International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy
¿Hay que restringir la fruta en el individuo con diabetes tipo 2 recién diagnosticado?
Christensen AS, Viggers L, Hasselström K, Gregersen S. Effect of fruit restriction on glycemic control in patients with type 2 diabetes - a randomized trial. Nutr J. 2013 Mar 5;12:29. doi: 10.1186/1475-2891-12-29.
Christensen AS, Viggers L, Hasselström K, Gregersen S. Effect of fruit restriction on glycemic control in patients with type 2 diabetes - a randomized trial. Nutr J. 2013 Mar 5;12:29. doi: 10.1186/1475-2891-12-29.
Existen diferencias entre la diabetes LADA (latent autoimmune diabetes) y la diabetes tipo 1 en el adulto.
Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Beck-Neilsen H, Tuomilehto J, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum WA, Williams R, Brophy S, Pozzilli P, Leslie RD; Action LADA consortium. Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype: Action LADA 7.
Diabetes Care. 2013 Apr;36(4):908-13. doi: 10.2337/dc12-0931. Epub 2012 Dec 17.
Mollo A, Hernandez M, Marsal JR, Esquerda A, Rius F, Blanco-Vaca F, Verdaguer J, Pozzilli P, de Leiva A, Mauricio D.Latent autoimmune diabetes (LADA) is perched between type 1 and type 2: evidence from adults in one region of Spain.
Diabetes Metab Res Rev. 2013 Mar 9. doi: 10.1002/dmrr.2411. [Epub ahead of print]
Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Beck-Neilsen H, Tuomilehto J, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum WA, Williams R, Brophy S, Pozzilli P, Leslie RD; Action LADA consortium. Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype: Action LADA 7.
Diabetes Care. 2013 Apr;36(4):908-13. doi: 10.2337/dc12-0931. Epub 2012 Dec 17.
Mollo A, Hernandez M, Marsal JR, Esquerda A, Rius F, Blanco-Vaca F, Verdaguer J, Pozzilli P, de Leiva A, Mauricio D.Latent autoimmune diabetes (LADA) is perched between type 1 and type 2: evidence from adults in one region of Spain.
Diabetes Metab Res Rev. 2013 Mar 9. doi: 10.1002/dmrr.2411. [Epub ahead of print]
¿Mejoran los inhibidores de los DPP-4 el riesgo cardiovascular? Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013 Feb;15(2):112-20. doi: 10.1111/dom.12000. Epub 2012 Sep 20.
La aplicación del Diabetes Prevention Program mejora claramente los indicadores metabólicos. Ma J, YankV, Xiao L, Lavori PW, Wilson SR, Rosas LG, Stafford RS. Translating the Diabetes Prevention Program Lifestyle Intervention for Weight Loss Into Primary Care: A Randomized Trial. Arch Intern Med. 2012 Dec 10:1-9. doi:10.1001/2013.jamainternmed.987. [Epub ahead of print]
Katula JA, Vitolins MZ, Morgan TM, Lawlor MS, Blackwell CS, Isom SP, Pedley CF, Goff DC Jr.The healthy living partnerships to prevent diabetes study: 2-year outcomes of a randomized controlled trial. Am J Prev Med. 2013 Apr;44(4 Suppl 4):S324-32. doi: 10.1016/j.amepre.2012.12.015
Katula JA, Vitolins MZ, Morgan TM, Lawlor MS, Blackwell CS, Isom SP, Pedley CF, Goff DC Jr.The healthy living partnerships to prevent diabetes study: 2-year outcomes of a randomized controlled trial. Am J Prev Med. 2013 Apr;44(4 Suppl 4):S324-32. doi: 10.1016/j.amepre.2012.12.015
Marzo 2013
Clara mejoría en los objetivos de control del individuo con diabétes tipo 2 en la National Health and Nutrition Examination Survey (NHANES). Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC.The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010. Diabetes Care. 2013 Feb 15. [Epub ahead of print].
La disponibilidad de azúcar por países explicaría la prevalencia de diabetes tipo 2 a nivel mundial. Basu S, Yoffe P, Hills N, Lustig RH (2013) The Relationship of Sugar to Population-Level Diabetes Prevalence: An Econometric Analysis of Repeated Cross-Sectional Data. PLoS ONE 8(2): e57873. doi:10.1371/journal.pone.0057873
La prevalencia de la enfermedad renal crónica en los individuos con diabetes tipo 2 en España. El estudio PERCEDIME2. Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J, Diez-Espino J, Mundet-Tuduri X, Barrot-De la Puente J, Coll-de Tuero G, and RedGDPS Study Group. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. BMC Nephrol. 2013 Feb 22;14(1):46. [Epub ahead of print].
Nueva revisión de la Cochrane sobre la prevención primaria cardiovascular con las estatinas. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2013 Jan 31;1:CD004816. doi: 10.1002/14651858.CD004816.pub5.
Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. doi: 10.1002/14651858.CD004816.pub4.
Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. doi: 10.1002/14651858.CD004816.pub4.
La terapia insulínica presenta peores resultados en salud que otras terapias hipoglucémicas. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes. J Clin Endocrinol Metab. 2013 Feb;98(2):668-77. doi: 10.1210/jc.2012-3042. Epub 2013 Jan 31.
Existe asociación estadística entre el peso y la mortalidad en los individuos con diabetes recién diagnosticados. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013 Jan 2;309(1):71-82. doi: 10.1001/jama.2012.113905.
Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, Golden SH, Liu K, Mukamal KJ, Campbell-Jenkins B, Dyer AR. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012 Aug 8;308(6):581-90. doi: 10.1001/jama.2012.9282.
Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, Golden SH, Liu K, Mukamal KJ, Campbell-Jenkins B, Dyer AR. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012 Aug 8;308(6):581-90. doi: 10.1001/jama.2012.9282.
¿Tiene mayor insulinoresistencia el hombre que la mujer? Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med. 2009;6 Suppl 1:60-75. doi: 10.1016/j.genm.2009.02.002.
La eficacia de las sulfonilureas. Una nueva revisión. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013 Mar 15. [Epub ahead of print]
Febrero 2013
El consumo de azúcar y el peso corporal. Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ. 2012 Jan 15;346:e7492. doi: 10.1136/bmj.e7492.
Consumir más de un huevo diario aumenta el riesgo coronario en los diabéticos pero no en los no diabéticos. Rong Y, Chen L, Zhu T, Song Y, Yu M, Shan Z, Sands A, Hu FB, Liu L. Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studies. BMJ. 2013 Jan 7;346:e8539. doi: 10.1136/bmj.e8539.
¿Es necesario inyectar la insulina humana regular 20 minutos antes de las comidas? Müller N, Frank T, Kloos C, Lehmann T, Wolf G, Müller UA. Randomized Crossover Study to Examine the Necessity of an Injection-to-Meal Interval in Patients With Type 2 Diabetes Mellitus and Human Insulin. Diabetes Care. 2013 Jan 22. [Epub ahead of print]
La sitagliptina y la glipizida en individuo diabético tipo 2 con enfermedad renal terminal en diálisis. Arjona Ferreira JC, Corry D, Mogensen CE, Sloan L, Xu L, Golm GT, Gonzalez EJ, Davies MJ, Kaufman KD, Goldstein BJ. Efficacyand Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD ReceivingDialysis: A 54-Week Randomized Trial. Am J Kidney Dis. 2013 Jan 23. pii:S0272-6386(12)01510-7. doi: 10.1053/j.ajkd.2012.11.043. [Epub ahead of print]
KDIGO 2012Clinical Practice Guideline for the Evaluation and Management of Chronic KidneyDisease. volume 3 | issue 1 | JANUARY2013
KDIGO 2012Clinical Practice Guideline for the Evaluation and Management of Chronic KidneyDisease. volume 3 | issue 1 | JANUARY2013
Distintas poblaciones según las pruebas utilizadas en el diagnóstico de la prediabetes en la edad escolar. Buse JB, Kaufman FR, Linder B, Hirst K, El Ghormli L, Willi S; HEALTHY Study Group. Diabetes screening with hemoglobin a1c versus fasting plasma glucose in a multiethnic middle-school cohort. Diabetes Care. 2013 Feb;36(2):429-35. doi: 10.2337/dc12-0295. Epub 2012 Nov 27.
La dieta mediterránea suplementada con aceite de oliva o frutos secos previene los eventos cardiovasculares. Estudio PREDIMED.
Salas-Salvadó J,Bulló M, Babio N, Martínez-González MA, Ibarrola-Jurado N, Basora J, et al, For the PREDIMED Study investigators. Reduction in the Incidence of Type 2-Diabetes with the Mediterranean Diet: Results of the PREDIMED-Reus Nutrition Intervention Randomized Trial. Diabetes care 2010. Published online before print October 7, 2010.
Estruch R, Ros E, Salas-Salvadó J, Covas MI, D Pharm, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; the PREDIMED Study Investigators.Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med. 2013 Feb 25. [Epub ahead of print]
Enero 2013
Salas-Salvadó J,Bulló M, Babio N, Martínez-González MA, Ibarrola-Jurado N, Basora J, et al, For the PREDIMED Study investigators. Reduction in the Incidence of Type 2-Diabetes with the Mediterranean Diet: Results of the PREDIMED-Reus Nutrition Intervention Randomized Trial. Diabetes care 2010. Published online before print October 7, 2010.
Estruch R, Ros E, Salas-Salvadó J, Covas MI, D Pharm, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; the PREDIMED Study Investigators.Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med. 2013 Feb 25. [Epub ahead of print]
Una aproximación a las indicaciones de la OMS en el diagnóstico de la diabetes. Postura sobre la utilización de la HbA1c en UK. John WG; UK Department of Health Advisory Committee on Diabetes. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med. 2012 Nov;29(11):1350-7. doi: 10.1111/j.1464-5491.2012.03762.x.
Standards of Medical Care in Diabetes 2013. AMERICAN DIABETES ASSOCIATION. Standards of Medical Care in Diabetes 2013
DIABETES CARE, VOLUME 36, SUPPLEMENT 1, JANUARY 2013
DIABETES CARE, VOLUME 36, SUPPLEMENT 1, JANUARY 2013
El tratamiento intensivo de los estilos de vida puede llevar a la remisión de la diabetes tipo 2. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, Pownall HJ, Johnson KC, Safford MM, Kitabchi AE, Pi-Sunyer FX, Wing RR, Bertoni AG; for the Look AHEAD Research Group. Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes. JAMA. 2012 Dec 19;308(23):2489-2496.
El sobrepeso y al obesidad grado 1º no influyen en la mortalidad. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013 Jan 2;309(1):71-82. doi: 10.1001/jama.2012.113905.
